Gilead inks another NASH collaboration

Gilead Sciences (Nasdaq: GILD) and drug discovery start-up insitro have entered into a strategic collaboration to discover and develop therapies for patients with non-alcoholic steatohepatitis (NASH), in a transaction worth as much as $1.05 billion to the latter firm, adding to a number of other research deals.

Under the terms of the three-year collaboration, insitro’s proprietary platform will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease. The insitro Human (ISH) platform applies machine learning, human genetics and functional genomics to generate and optimize unique in vitro models and drive therapeutic discovery and development. The ISH platform will provide insights into disease progression, suggest candidate targets, and predict patient responses to potential therapeutic interventions. Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.

Financial terms